$3+ Billion Worldwide Pediatric Interventional Cardiology Industry to 2027 - Featuring Boston Scientific, Cardinal Health, Edwards Lifesciences and General Electric Among Others

04 Oct 2022
www.prnewswire.com
DUBLIN, Oct. 4, 2022 /PRNewswire/ -- The "Pediatric Interventional Cardiology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to
ResearchAndMarkets.com's offering.
The global pediatric interventional cardiology market reached a value of US$ 2.28 billion in 2021. Looking forward, the market is projected to reach a value of US$ 3.46 billion by 2027, exhibiting a CAGR of 6.80% during 2022-2027.
Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Pediatric interventional cardiology is a subset of cardiology that involves the use of specific catheter-based techniques to treat heart disorders in infants, children, and adolescents up to 18 years of age. They include balloon angioplasty, coil occlusion, stent implantation, and aortic valve stenosis.
As compared to conventional cardiological treatments, pediatric interventional cardiology is more minimally invasive, thus reducing post-surgery complications. Consequently, they are extensively employed for performing angioplasty, valvuloplasty, coronary thrombectomy, and congenital heart defect correction procedures across clinical testing laboratories, hospitals, cardiac centers, and research institutes.
The increasing instances of various congenital cardiac diseases in children, such as atrial septal defect (ASD), atrioventricular canal defect, patent ductus arteriosus (PDA), and ventricular septal defect (VSD) represent one of the key factors driving the pediatric interventional cardiology market growth. The introduction of novel and more efficient pediatric interventional cardiology devices, including catheters, bio-absorbable stents, guidewires, balloons, stents, vascular closure devices, atherectomy devices is acting as another major growth-inducing factor.
In line with this, the shifting inclination of patients toward non-invasive medical treatment procedures, along with the rising awareness regarding the associated benefits, such as lower risk of infection, shorter postoperative recovery times, and avoidance of large scars is also driving the market growth.
Other factors, including rising healthcare expenditure and the numerous initiatives being undertaken by governments of various nations to speed-up regulatory procedures, are creating a positive outlook for the market. The market is also driven by extensive research and development (R&D) activities, increasing consumer healthcare expenditure and investments by governments and non-government organizations (NGOs) for strengthening the existing healthcare infrastructure, and significant technological advancements in the field of cardiology.
Key Questions Answered in This Report
How has the global pediatric interventional cardiology market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global pediatric interventional cardiology market?
What are the key regional markets?
What is the breakup of the market based on the device type?
What is the breakup of the market based on the procedure?
What is the breakup of the market based on the End-use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global pediatric interventional cardiology market and who are the key players?
What is the degree of competition in the industry?
Key Topics Covered:
2 Scope and Methodology
3 Executive Summary
4.1 Overview
4.2 Key Industry Trends
5 Global Pediatric Interventional Cardiology Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Device Type
6.1 Closure Devices
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Transcatheter Heart Valves
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Atherectomy Devices
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Catheters
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Balloons
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Stents
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Procedure
7.1 Catheter-Based Valve Implantation
7.1.1 Market Trends
7.1.2 Market Forecast
7.2.1 Market Trends
7.2.2 Market Forecast
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Coronary Thrombectomy
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by End Use
8.1 Clinical Testing Laboratories
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Hospitals
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cardiac Centers
8.3.1 Market Trends
8.3.2 Market Forecast
8.4.1 Market Trends
8.4.2 Market Forecast
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Region
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 SWOT Analysis
14.3.2 Boston Scientific Corporation
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 NuMED Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/cboik2
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.